ICP-248
- Generic Name
- ICP-248
InnoCare's Orelabrutinib Shows Over 90% Reduction in MS Brain Lesions in Phase II Trial
• Orelabrutinib demonstrated remarkable efficacy in Phase II trials, reducing new brain lesions by 90.4% at 12 weeks and 92.3% at 24 weeks compared to placebo in RRMS patients.
• The BTK inhibitor, administered at 80mg once daily, showed promising results for relapsing-remitting multiple sclerosis treatment, marking a significant advancement in MS therapy.
• InnoCare Pharma presented these breakthrough findings at the ACTRIMS Forum 2025, positioning the company as an emerging leader in neuroimmunology therapeutics.
InnoCare's BCL2 Inhibitor ICP-248 Combination Therapy Advances to Phase III Trial for First-line CLL/SLL Treatment in China
• China's NMPA has approved InnoCare's registrational Phase III trial of BCL2 inhibitor ICP-248 (Mesutoclax) combined with orelabrutinib for first-line CLL/SLL treatment.
• The ICP-248 and orelabrutinib combination demonstrated promising efficacy and safety in Phase II trials, offering potential for deeper remission in treatment-naïve CLL/SLL patients.
• With global CLL incidence at 191,000 new cases annually and rising rates in China, this fixed-duration combination therapy represents a significant advancement in treatment options.
InnoCare Pharma's ICP-488 Demonstrates Positive Phase II Results for Psoriasis
• InnoCare Pharma's ICP-488 achieved positive Phase II clinical trial results for psoriasis, addressing the demand for new oral medications in China.
• The company's revenue is projected to grow by 26.4% annually, driven by strong product demand, including its innovative EcoSmart line.
• InnoCare faces financial challenges, including unprofitability and operational inefficiencies, impacting its valuation despite trading below fair value.
• Strategic initiatives, such as ICP-488 and ICP-248 trials, offer growth opportunities, but economic factors and competition pose threats.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath